Lombard Medical Technologies PLC Satisfaction of FDA Milestone Requirements (8614Z)
March 13 2013 - 6:25AM
UK Regulatory
TIDMLMT
RNS Number : 8614Z
Lombard Medical Technologies PLC
13 March 2013
Press Information
Lombard Medical Technologies PLC
("Lombard Medical" or "the Company")
Satisfaction of FDA Milestone Requirements
for the Second Tranche of the May 2011 Fundraising
London, UK, 13 March 2013 - Lombard Medical Technologies PLC
(AIM: LMT), the specialist medical technology company focused on
innovative vascular products, announces the determination of
satisfaction of the FDA Milestone requirements for the Second
Tranche of the two tranche placing and subscription announced by
the Company on 20 April 2011 (the "May 2011 Fundraising").
This determination is the trigger for the transfer of the
GBP14.1m Second Tranche subscription monies and the application for
admission of shares on the London Stock Exchange both of which are
anticipated by the middle of April 2013.
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device
company focused on device solutions for the $1.2 billion dollar per
annum abdominal aortic aneurysm (AAA) repair market. AAAs are a
balloon-like enlargement of the aorta which, if left untreated, may
rupture and cause death. Approximately 4.5 million people are
living with AAAs in the developed world and each year 600,000 new
cases are diagnosed. The market for endovascular stent grafts for
this application is expected to grow to $1.6 billion by 2015. The
Company's lead product, Aorfix(TM), is an endovascular stent graft
which has been specifically designed to solve the problems that
exist in treating complex tortuous anatomy which is often present
in advanced AAA disease. Aorfix(TM) is currently being
commercialised in the EU, and has been approved by the FDA in the
US
The Company is headquartered in Oxfordshire, with operations in
Ayrshire and Phoenix, USA.
Further background on the Company can be found at
www.lombardmedical.com.
For further information:
Lombard Medical Technologies PLC Tel: 01235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited Tel: 020 7523 8000
Lucy Tilley/ Henry Fitzgerald O'Connor
/ Tim Redfern
FTI Consulting Tel: 020 7831 3113
Simon Conway / Susan Stuart / Victoria
Foster Mitchell
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCNKBDDNBKBNND
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2024 to Jul 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024